Please assess the completion status of the following clinical trial:

Trial Title: Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed recurrent, persistent or metastatic cervical carcinoma (squamous or adenocarcinoma), with no potentially curative standard treatment~* Measurable disease or evaluable disease~PATIENT CHARACTERISTICS:~Age:~* 18 to physiological 60~Performance status:~* ECOG 0-2~Life expectancy:~* Greater than 2 months~Hematopoietic:~* WBC greater than 3000/mm3~* Platelet count greater than 100,000/mm3~Hepatic:~* Bilirubin less than 1.5 times normal~* SGOT/SGPT less than 1.5 times normal~Renal:~* BUN less than 1.5 times normal~* Creatinine less than 1.5 times normal~* Creatinine clearance greater than 50 mL/min~Other:~* Ineligible for other high priority national or institutional study~* Not pregnant or nursing~* HIV negative~* No prior malignancy except nonmelanoma skin cancer~* No serious medical or psychiatric illness preventing treatment or informed consent~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Greater than 4 weeks since prior chemotherapy~* No greater than 2 prior chemotherapy regimens~* No prior taxane or camptothecin~Endocrine therapy:~* No concurrent hormonal therapy except that required for nondisease related conditions (e.g., insulin for diabetes)~Radiotherapy:~* Greater than 4 weeks since prior radiation therapy~* No concurrent radiation therapy~Surgery:~* Greater than 4 weeks since prior surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).